SDGR
$12.29
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally.
Recent News
How The Schrödinger (SDGR) Investment Story Is Evolving With Hosted Software And Reset Targets
Schrödinger’s updated analyst framework trims its fair value estimate from US$27.30 to US$23.50, roughly a 14% reset to the price target. This shift aligns with recent research that balances long term optimism about the business model with more caution around near term execution, valuation, and the move toward hosted software. As you read on, you will see how these changing targets fit into the broader analyst narrative and what to watch as it evolves. Stay updated as the Fair Value for...
Schrödinger, Inc. (SDGR) Transition to Licensing Model Triggers Robust Revenue Growth
Schrodinger Inc. (NASDAQ:SDGR) is one of the best cancer stocks to invest in now. On February 25, Schrodinger Inc. (NASDAQ:SDGR) delivered solid fourth-quarter and full-year 2025 results characterized by robust revenue growth. The company also announced it is accelerating its transition to a licensing model to establish a more predictable, higher-visibility revenue stream. Full-year revenue […]
Assessing Schrödinger (SDGR) Valuation After Full Year 2025 Earnings And AI Platform Progress
Schrödinger (SDGR) is back on investors’ radar after its full year 2025 earnings, with total revenue of about US$255.9 million, sales of US$56.4 million, and a narrower net loss of US$103.3 million. See our latest analysis for Schrödinger. Despite the solid 2025 revenue update and progress on reducing losses, Schrödinger’s recent share price performance has been weak. The 30 day share price return is 13.67% and the year to date share price return is 32.93%, while the 1 year total shareholder...
Schrodinger Q4 Earnings Call Highlights
Schrodinger (NASDAQ:SDGR) executives used the company’s fourth-quarter and full-year 2025 earnings call to emphasize progress in its software business, a sharp increase in drug discovery revenue, and a shift in how investors should evaluate near-term performance as the company accelerates its transi
Schrodinger Inc (SDGR) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Transition ...
Schrodinger Inc (SDGR) reports a 23% revenue increase and strategic advancements, despite facing margin pressures and a challenging biotech environment.